News
![Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update on OPC1
![Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Clovis Oncology kündigt Erstattung für Rubraca®-Tabletten (Rucaparib) für Frauen mit rezidivierendem Eierstockkrebs in Italien an](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology kündigt Erstattung für Rubraca®-Tabletten (Rucaparib) für Frauen mit rezidivierendem Eierstockkrebs in Italien an
Clovis Oncology, Inc. (NASDAQ: CLVS), hat heute bekannt gegeben, dass die italienische Arzneimittelagentur AIFA die Erstattung von Rucaparib in Italien zugelassen hat. Rucaparib wird demnächst als
![Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic
![Aurinia Announces Updates to the Board of Directors](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Aurinia Announces Updates to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory
![ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
ArQule to Participate in the Jefferies London Healthcare Conference on November 20, 2019
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK.
![Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for
![Savara to Present at the Stifel 2019 Healthcare Conference](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Savara to Present at the Stifel 2019 Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New
![Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, reported financial and operating
![NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) today announced promising results from its pre-clinical collaboration1 with The University of
![Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market
![Sangamo Therapeutics Reports Third Quarter 2019 Financial Results](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights.
“We continue to prioritize and progress
![Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical
![Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner in Greater China, CANbridge Pharmaceuticals Inc., has received registration approval from the Department of Health in
![Updated Results from Phase 2 SPiReL Study Evaluating IMV’s DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Updated Results from Phase 2 SPiReL Study Evaluating IMV’s DPX-Survivac as Combination Therapy in Patients with r/r DLBCL to be Presented at 61st American Society of Hematology (ASH) Annual Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that updated results from SPiRel, a Phase 2 study of the
![Puma Biotechnology to Present at the Credit Suisse Healthcare Conference](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
![IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
IMV to Present Clinical Translational Data from DeCidE1 Study of DPX-Survivac at SITC 2019 Annual Meeting
IMV Inc. (Nasdaq:IMV)(TSX:IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that translational data, including comprehensive immune
![Puma Biotechnology Reports Third Quarter 2019 Financial Results](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Puma Biotechnology Reports Third Quarter 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for
![Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report
![IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update
IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter
![Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic
![Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today
![Clovis Oncology Announces Third Quarter 2019 Operating Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Clovis Oncology Announces Third Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and